1. Home
  2. ACET vs BEDU Comparison

ACET vs BEDU Comparison

Compare ACET & BEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.54

Market Cap

93.5M

Sector

Health Care

ML Signal

HOLD

Logo Bright Scholar Education Holdings Limited each  representing four

BEDU

Bright Scholar Education Holdings Limited each representing four

HOLD

Current Price

$2.19

Market Cap

65.0M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACET
BEDU
Founded
1947
1994
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
93.5M
65.0M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ACET
BEDU
Price
$0.54
$2.19
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
1.9M
4.7K
Earning Date
11-05-2025
01-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$224,321,752.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$1.35
52 Week High
$1.12
$2.28

Technical Indicators

Market Signals
Indicator
ACET
BEDU
Relative Strength Index (RSI) 33.71 57.57
Support Level $0.53 $2.14
Resistance Level $0.57 $2.22
Average True Range (ATR) 0.05 0.03
MACD 0.00 -0.00
Stochastic Oscillator 5.35 43.75

Price Performance

Historical Comparison
ACET
BEDU

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About BEDU Bright Scholar Education Holdings Limited each representing four

Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom and the United States. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.

Share on Social Networks: